Effects of EGFR, CK19, CK20 and Survinin Gene Expression on Radiotherapy Results in Patients with Locally Advanced Head and Neck Cancer

  • Kekilli, Kezban Esra (Department of Radiation Oncology, Bursa Ali Osman Sonmez Oncology Hospital) ;
  • Abakay, Candan Demioz (Faculty of Medicine, Uludag University) ;
  • Tezcan, Gulcin (Department of Medical Biology, Uludag University) ;
  • Tunca, Berrin (Department of Medical Biology, Uludag University) ;
  • Egeli, Unal (Department of Medical Biology, Uludag University) ;
  • Saraydaroglu, Ozlem (Department of Pathology, Uludag University) ;
  • Esbah, Onur (Department of Medical Oncology) ;
  • Ekinci, Ahmet Siyar (Department of Medical Oncology) ;
  • Arslan, Sonay (Diyarbakir Gazi Yasargil Education and Research Hospital) ;
  • Uslu, Nuri (Diyarbakir Gazi Yasargil Education and Research Hospital) ;
  • Ozkan, Lutfi (Faculty of Medicine, Uludag University)
  • Published : 2015.04.14


Purpose: To investigate the effects of epidermal growth factor receptor (EGFR), cytokeratin 19 (CK19), cytokeratin 20 (CK20) and survinin gene expression on local control (LC) and overall survival (OS) in patients with locally advanced head and neck cancer (LAHNC) who were administered radiotherapy (RT). Materials and Methods: Twenty-six patients who were admitted to Uludag University Medical Faculty Department of Radiation Oncology with a diagnosis of LAHNC (GIII-GIV) were included in this study. Gene expression was evaluated in tumor tissues and peripheral blood. RNA isolation was performed on paraffinized tumor tissues and peripheral blood samples obtained before RT (BR). The densities of the obtained RNAs were analyzed at 260/280 nm. cDNA samples obtained from total RNA,EGFR, CK19, CK20 and survinin gene expression levels were assessed via the Sybr Green method and data were analyzed with the ${\Delta}{\Delta}Ct$ method. The same process was repeated for peripheral blood samples taken after RT (AR). Results: The female/male ratio was 3:23 and the mean age was 56.5 years (38-75years). After radiotherapy, CK19 and CK20 levels in the peripheral blood were found to be correlated according to Pearson correlation analysis(p=0.049). This result indicates a possibility of remaining positive for CK19 and CK20 in the peripheral blood even after RT in patients with CK19, CK20, and EGFR positive tumors before RT. There was a statistically significant correlation between survinin levels measured BR and AR (p=0.028). Conclusions: In this study, we found that patients with any EGFR, CK19, CK20 or survinin positivity in their peripheral blood obtain less benefit from radiotherapy. A wider patient population and advanced protein analyses are necessary in order to increase the reliability of our findings.


Locally advanced head and neck cancer;EGFR;CK19;CK20;survinin;gene expression;radiotherapy


  1. Andratschke M, Pauli C, Stein M, et al (2003). MHC-class I antigen expression on micrometastases in bone marrow of patients with head and neck squamous cell cancer. Anticancer Res, 23, 1467-71.
  2. Cooper JS, Porter K, Malin K (2009). National cancer database report on cancer of the head and neck:10 year update Head Neck. DETAILS??
  3. Farnebo L, Jerhammar F, Ceder R, et al (2011). Combining factors on protein and gene level to predict radioresponse in head and neck cancer cell lines. J Oral Pathol Med, 40, 739-46.
  4. Forastiere AA, Ang KK, Brizel D, et al (2008). National comprehensive cancer network, head and neck cancers. J Natl Compr Canc Netw, 646-95
  5. Khan Z, Khan N, Tiwari RP, et al (2010). Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. Radiother Oncol, 96, 267-73.
  6. Lin JC, Wang WY, Chen KY, et al (2004). Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med, 350, 2461-70.
  7. Toyoshima T, Vairaktaris E, Nkenke E, et al (2009). Hematogenous cytokeratin 20 mRNA Detection has prognostic impact in oral sguamous cell carsinoma. preliminary results. Anticancer Res, 29, 291-97.
  8. Tunca B, Egeli U, Cecener G, et al (2012). CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer. Tumori, 98, 243-51.
  9. Shimada R, Iinuma H, Akahane T, et al (2012). Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients. Oncol Rep, 27, 947-53.
  10. Venook AP (2005). Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer, 103, 2435-46.
  11. Wollenberg B, Walz A, Kolbow K, et al (2004). Clinical relevance of circulating tumour cells in the bone marrow of patients with SCCHN. Onkologie, 27, 358-62.
  12. Yang RN, Yang SH, Chang CC, et al (2010). Upregulation of fecal cytokeratin 19 is associated with prognosis in older colorectal cancer patients. Genet Test Mol Biomarkers, 14, 703-08.
  13. Zhao S, Liu Y, Zhang Q, et al (2011). The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature. Breast Cancer Res Treat, 130, 809-16.
  14. Zhong LP, Chen WT, Zhang CP, et al (2007). Increased CK19 expression correlated with pathologic differantiation grade and prognosis in oral sguamous cell carcinoma patients. Oral Surg Oral Pathol Oral Radiol Endod, 104, 377-84
  15. Zhu H, Wang Q, Hu C, et al (2011). High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. Tumour Biol, 32, 1147-53.
  16. Zimmerman M, Zauhair A, Ozsahin M (2006). The epidermal growth factor reseptor (EGFR) in head and neck cancer its role and treatment implications, Radiat Oncol, 1, 11.

Cited by

  1. miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation vol.45, pp.9, 2016,